Bromfenac Ocular Formulation pH Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bromfenac formulations for ocular use have limitations in bioavailability and efficacy, particularly at higher pH levels, which can lead to reduced drug penetration and effectiveness in treating ocular inflammation and pain, especially after cataract surgery.
Innovation Solution
A bromfenac formulation with a pH between 6.0 and 8.3, containing bromfenac concentrations between 0.02% and 0.20%, is topically administered to enhance bioavailability and efficacy, with the inclusion of excipients like tyloxapol, povidone, and benzalkonium chloride, allowing for comparable or better efficacy at lower concentrations than traditional 0.09% solutions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bromfenac is formulated at higher pH levels (traditional formulations), then the formulation is more stable and easier to manufacture, but ocular bioavailability and drug penetration are reduced
Solution Approach 1:
The patent changes the pH parameter of the bromfenac formulation from traditional higher pH levels to a controlled range of 6.0-8.3, which fundamentally alters the drug's ionization state and penetration characteristics. This parameter change enables improved ocular bioavailability while maintaining formulation stability through optimized excipient combinations.
2Device complexity
If traditional 0.09% bromfenac solutions are used, then the formulation is simple and well-established, but efficacy is limited due to reduced drug penetration at higher pH
Solution Approach 1:
The patent creates a composite formulation by combining bromfenac with specific excipients (tyloxapol, povidone, benzalkonium chloride) in optimized ratios. This composite approach enhances drug penetration and therapeutic efficacy beyond what simple bromfenac solutions can achieve, while maintaining practical formulation complexity.
3Object-affected harmful factors
If lower bromfenac concentrations are used to improve safety profile, then the benefit-to-safety ratio improves, but efficacy may be compromised without enhanced penetration
Solution Approach 1:
By changing the pH parameter to 6.0-8.3, the patent enables lower bromfenac concentrations (0.02%-0.20%) to achieve equivalent or superior efficacy compared to traditional formulations. The optimized pH enhances drug penetration and retention, allowing reduced dosing concentrations that improve the benefit-to-safety ratio.
4Reliability
If multiple daily administrations are required to maintain therapeutic levels, then adequate drug penetration can be achieved, but patient convenience and compliance decrease
Solution Approach 1:
The optimized formulation achieves sustained therapeutic levels through improved drug retention and penetration characteristics. The pH-optimized composition maintains adequate drug concentrations in ocular tissues for extended periods, enabling once-daily administration and improving patient compliance while maintaining continuous therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves enhanced bromfenac levels in ocular tissues, providing effective pain relief and inflammation reduction comparable to 0.09% solutions at lower concentrations, thus improving the benefit-to-safety ratio and convenience of once-daily administration.
Implementation Method 1
The inventive bromfenac formulations and methods disclosed were similar to the BROMDAY TM formulations, except that the pH of the formulations was reduced to a pH between pH 6.0 and pH 8.3, and in some embodiments, to a pH between pH 7.0 and pH 8.2
Data Source
Figure 1A~1C
Figure 2
Figure 3
AI summary
Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY™ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.